TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01324258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Part1 and Part2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Part2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Part2
Study: NCT01074190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1
Description: A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2
Description: A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 3
Description: A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
Study: NCT02474732

Intervention type: DEVICE
Group type: OTHER
Intervention: Beactive(r) Brace
Description: Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
Study: NCT03641066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Brace
Description: Each participant will complete the 1 minute walking and 2 minute running under 5 conditions \[1\] un-braced, \[2\] Active Ankle 329 Ankle Sleeve, \[3\] AS1Pro (a lace-up brace), \[4\] Eclipse 1 (single-upright brace), and \[5\] Eclipse 2 (double upright brace)
Study: NCT00976222

Intervention type: DRUG
Group type: OTHER
Intervention: intravitreal injection with ranibizumab
Description: 0.5 mg in 0.05 ml, monthly, 12 months
Study: NCT06330389

Intervention type: PROCEDURE
Intervention: Burn Injuries Graft Surgery
Description: Burn Injuries Graft Surgery
Study: NCT01628588

Intervention type: DRUG
Intervention: bimatoprost 0.01%
Description: Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
Study: NCT02912572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib will be taken twice per day by mouth Each Cycle lasts 28 days
Study: NCT01970995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THS 2.2 Menthol (mTHS 2.2)
Description: THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence (SA)
Description: SA for 5 days in confinement prolonged by 85 days in an ambulatory setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Menthol Conventional Cigarette (mCC)
Description: Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
Study: NCT01698164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol plus MPA
Description: Participants are given estradiol and synthetic progestin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ximingting Tablet
Description: Participants are given phytoestrogen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol plus progesterone
Description: Participants are given estradiol and natural progesterone.
Study: NCT01923597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Green tea extract
Description: 200mg/capsule Administered orally 4 capsules per day For 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Green tea extract
Description: 200mg/capsule Administered orally 4 capsules per day For 3 months
Study: NCT04225923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-21 Low dose
Description: NPC-21 will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-21 High dose
Description: NPC-21 will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPC-21 Placebo
Description: Placebo will be administered via an approximately 60-minute intravenous infusion on Day 1 and at Week 4, 8, 12
Study: NCT03001050

Intervention type: DEVICE
Group type: OTHER
Intervention: PINPOINT System
Description: To use the camera probe and identify the tendon and footprint vascularity at the time of surgery
Study: NCT00482430

Intervention type: DRUG
Group type: OTHER
Intervention: MK0557
Description: MK0557 10mg tablet qd for a 15-wk treatment period

Intervention type: DRUG
Group type: OTHER
Intervention: MK0557
Description: MK0557 10mg tablet qd for a 15-wk treatment period

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: Placebo (unspecified)
Description: MK0557 Pbo tablet qd for a 15-wk treatment period

Intervention type: DRUG
Group type: OTHER
Intervention: Comparator: Placebo (unspecified)
Description: MK0557 Pbo tablet qd for a 15-wk treatment period
Study: NCT02919878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nucleoside analog- Chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: XRT
Description: pre-operative radiotherapy given concurrently with Gemcitabine chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
Study: NCT00390754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education for pregnancy planning
Description: Provision of free home pregnancy tests to women at risk for unintended pregnancy
Study: NCT01576549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered subcutaneously
Study: NCT01319695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitropin alfa
Description: 100 microg for a group of women weighing \<or=60 kg and 150 microg for a group of women weighing \>60 kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant follicle stimulating hormone (FSH)
Description: 150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are \>18mm
Study: NCT03150771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Injection
Study: NCT03656861

Intervention type: OTHER
Intervention: Physical load
Description: The impact of training on cardiac structure and function depends on the type, intensity and duration of the activity, as well as previous physical activity engagement, genetics and gender type. More knowledge about cardiac pathophysiologic training adaptation is needed.
Study: NCT02170285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional TDCS
Description: The primary intervention will be cathodal (inhibitory) tDCS over non-lesioned M1. This will be targeted using TMS baseline mapping data and neuronavigation (Brainsight2, Rogue Research, Montreal) individualized to the subjects MRI. Soft, replaceable 25cm2 electrodes will be placed over clean, dry scalp with the cathode over marked M1 and the reference electrode over contralateral forehead/orbit consistent with standard protocols. The current-controlled DC stimulator (neuroConn GmbH, Ilmenau, GE) will be turned up slowly over 30 seconds to the treatment current of 1.0 mA. TDCS will be administered each day during the first 20 minutes of the 90 minute therapy session. Child, family, and both treating and measuring occupational therapists are blinded to treatment allocation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TDCS
Description: Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
Study: NCT02779374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation
Description: Bone marrow aspiration of 10 ml/kg is done from the posterior iliac crest. The sample is put in sterile container with appropriate amount of heparin then filtered to remove bone spicules, fat, and cellular debris. The filtered sample is injected unprocessed in a peripheral vein. The process is done once.
Study: NCT01741649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clorhexidine
Description: Cleaning of the surgical site previous to the incision with a clorhexidine solution for five minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Povidone
Description: Cleaning of the surgical site previous to the incision with a povidone solution for five minutes.
Study: NCT04081363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: Extended-release and immediate-release capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: Extended-release and immediate-release capsules.
Study: NCT04362280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReCHARGE
Description: During their PE class, all participants (both arms) participate in an intensive lifestyle intervention with established efficacy among this population for the academic fall semester. The following semester, participants are randomized to different treatment arms. ReCHARGE increases the intensity of treatment provided in the first semester by increasing social support and addressing common barriers youth have to adhering to intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: PE class as usual led by PE teacher.
Study: NCT02043535

Intervention type: DEVICE
Group type: OTHER
Intervention: Delivery of precise levels of carbon dioxide with the RA-MR™ Virtual Sequential Gas Delivery System.
Description: All participants will undergo a baseline rest Rb-82 positron emission tomography (PET) myocardial perfusion imaging scan (MPI) with low-dose computed tomography. Following this baseline study, serial Rb-82 PET MPI using a target level of carbon dioxide (CO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A rest/stress Rb-82 PET MPI will be performed after return to normal CO2 levels (normocapnea) using persantine as the stress agent.~Myocardial perfusion stress testing

Intervention type: DEVICE
Group type: OTHER
Intervention: Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system
Description: All participants will undergo a baseline rest Rb-82 positron emission tomography myocardial perfusion imaging scan (PET MPI) with low-dose CT. Following this baseline study, serial Rb-82 PET MPI using three target levels of pulmonary end-tidal carbon dioxide tension (PetCO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A second rest Rb-82 PET MPI will be performed after return to normocapnea, followed by a pharmacologic persantine stress Rb-82 PET MPI.
Study: NCT00371293

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Program
Description: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Program
Description: Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP therapy
Description: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Description: Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.
Study: NCT01121133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: navitoclax
Description: Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.
Study: NCT02234154

Intervention type: DEVICE
Group type: OTHER
Intervention: TOPS System
Description: Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
Study: NCT04231149

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test product 2
Description: Test catheter 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test product 2
Description: Test catheter 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test product 3
Description: Test catheter 3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test product 3
Description: Test catheter 3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: SpeediCath Flex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator
Description: SpeediCath Flex
Study: NCT02060578

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire and interview
Description: Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
Study: NCT02526342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V.A.C. UltraTM (KCI®,San Antonio, Texas, USA)
Description: Free muscle flaps are treated with Negative Pressure Wound Therapy (V.A.C. Ultra (KCI®,San Antonio, Texas, USA)) for five days following surgery with a continuous subatmospheric pressure of 125 mmHg.
Study: NCT03015259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol fumarate dihydrate
Description: Experimental: Treatment 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort
Description: Active Comparator: Treatment 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Treatment 3
Study: NCT03232086

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean Air
Description: Each subject will be exposed to clean air for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PM2.5
Description: Each subject will be exposed up to 35-50 μg/m3 PM2.5 for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
Study: NCT00143312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: Voriconazole is given to patients at least 48 hours after chemotherapy
Study: NCT02244567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 850 mg twice daily for 3 months
Description: This drug is insulin sensitizing agent which will be given twice daily orally for 3 months for PCOS patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serum uc-oc
Description: Serum uc-oc is a bone biomarker involved in incraesing insulin in pathophysiology of PCOS. It will be measured in serum of pcos patients before and after treatment with metformin for 3 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: drug
Description: This group of patients will receive any type of vitamin as a placebo to compare with effect of Metformin on serum UC-OC.
Study: NCT02709564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 400 sublingual
Description: patients will take 2 tablets of sublingual misoprostol 400 microgram 3 hours and 1 hour before the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 400 sublingual
Description: patients will take 2 tablets of sublingual placebo 400 microgram 1 hour before the surgery
Study: NCT04123782

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: F-ESW Treatment
Description: The biological principles on which is based Focused Shockwave Treatment (F-ESWT) is has been demonstrated mostly in terms of improvement of Platelet Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Insulin Growth Factor-1 (IGF-1) and Transforming Growth Factor b1 (TGF-b1).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo F-ESW Treatment
Description: Very low concentration of F-ESW.
Study: NCT01856881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 876
Description: Ascending multiple doses of study drug administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 876
Description: Ascending multiple doses of study drug administered SC
Study: NCT03341962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838
Description: IMU-838 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838
Description: IMU-838 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838
Description: IMU-838 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838
Description: IMU-838 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838
Description: IMU-838 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838
Description: IMU-838 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets manufactured to mimic IMU-838 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets manufactured to mimic IMU-838 tablets
Study: NCT01796327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib oral
Description: Dacomitinib 45 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib intravenous
Description: Dacomitinib 20 mg solution will be given as 1 hour intravenous infusion
Study: NCT01963312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Supraselective Embolization of the prostate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of the prostate
Study: NCT03831594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galvanic Vestibular Stimulation
Description: Electrical current (under 1.5mA) applied to the mastoid processes to stimulate the balance organs in the inner ear

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy
Description: 45 minutes of standard physiotherapy treating impairments and functional problems

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy
Description: 45 minutes of standard physiotherapy treating impairments and functional problems
Study: NCT02866474

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: population living at home with meals on wheels

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: population living in an EHPAD
Study: NCT01081249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then intranasal oxytocin
Description: Participant received intranasal placebo spray at first psychotherapy session, and received a single dose of 40 IU intranasal oxytocin at the second session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin then placebo
Description: Participant received a single dose of 40 IU intranasal oxytocin at the first psychotherapy session, and received a similar dose of intranasal placebo spray at the second session.
Study: NCT00967551

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Sprinkles with zinc
Description: Daily dose of 1 packet of sprinkles

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient sprinkles without zinc
Description: I packet of micronutrient sprinkles without zinc